Abstract
Novel therapies for treating rheumatoid arthritis (RA) will largely be developed as a consequence of our improved understanding of immune-mediated inflammatory responses that regulate the progression of the disease process. This Special Mini “Hot-Topic” Issue of Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, entitled, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development explores several recent developments in how new drugs will be designed for the therapy of RA by employing proteomic databases and other wellvalidated computational strategies. Furthermore, recent advances in the recognition that pro-inflammatory cytokines and the interferon family of proteins activate intracellular signal transduction pathways which control immune-mediated inflammatory responses as well as the way in which newly identified regulators of inflammation such as the Toll-like receptors contribute to RA are also discussed.
Keywords: Computational strategies, proinflammatory cytokines, interferons, proteomic databases, signal transduction pathways, Toll-like receptors, lymphocyte, anti-interleukin
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Title: Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction
Volume: 10 Issue: 2
Author(s): Charles J. Malemud
Affiliation:
Keywords: Computational strategies, proinflammatory cytokines, interferons, proteomic databases, signal transduction pathways, Toll-like receptors, lymphocyte, anti-interleukin
Abstract: Novel therapies for treating rheumatoid arthritis (RA) will largely be developed as a consequence of our improved understanding of immune-mediated inflammatory responses that regulate the progression of the disease process. This Special Mini “Hot-Topic” Issue of Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, entitled, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development explores several recent developments in how new drugs will be designed for the therapy of RA by employing proteomic databases and other wellvalidated computational strategies. Furthermore, recent advances in the recognition that pro-inflammatory cytokines and the interferon family of proteins activate intracellular signal transduction pathways which control immune-mediated inflammatory responses as well as the way in which newly identified regulators of inflammation such as the Toll-like receptors contribute to RA are also discussed.
Export Options
About this article
Cite this article as:
J. Malemud Charles, Molecular Mechanisms in Rheumatic Diseases: Rationale for Novel Drug Development – Introduction, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry 2011; 10 (2) . https://dx.doi.org/10.2174/1871523011107020073
DOI https://dx.doi.org/10.2174/1871523011107020073 |
Print ISSN 1871-5230 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-614X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine Gene Therapy Strategies to Prevent Autoimmune Disorders
Current Gene Therapy Body Mass Index Impact on Disease Activity, Clinical and Sonographic Remission Rates in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews Economic and Cost-Effectiveness Considerations for Pharmacogenetics Tests: An Integral Part of Translational Research and Innovation Uptake in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Receptor Binding Ligands to Image Infection
Current Pharmaceutical Design Endothelial Dysfunction: Methods of Assessment and Application to Hypertension
Current Pharmaceutical Design The Role of Progenitor Cells in Osteoarthritis Development and Progression
Current Stem Cell Research & Therapy Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design Intravenous Immunoglobulin Therapy in Dermatologic Disorders
Inflammation & Allergy - Drug Targets (Discontinued) The NF-kB Pathway as a Potential Target for Autoimmune Disease Therapy
Current Pharmaceutical Design Skeletal Effects of Systemic and Topical Corticosteroids
Current Drug Safety A Review of HPLC Methods Used for Determining the Presence of Meloxicam
Current Pharmaceutical Analysis Parkinsons Disease and Obsessive-Compulsive Phenomena: A Systematic Review
Current Psychiatry Reviews Extracellular Tropomyosin: A Novel Common Pathway Target for Anti- Angiogenic Therapy
Current Cancer Drug Targets Role of Defensins and Cathelicidin LL37 in Auto-Immune and Auto- Inflammatory Diseases
Current Pharmaceutical Biotechnology Global Safety of Coxibs and NSAIDs
Current Topics in Medicinal Chemistry Pharmacological Management of PDA: Oral Versus Intravenous Medications
Current Clinical Pharmacology Chronotherapeutic Drug Delivery from Indomethacin Compression Coated Tablets for Early Morning Pain Associated Rheumatoid Arthritis
Current Drug Delivery Analytical and Pharmacological Aspects of Therapeutic Drug Monitoring of mTOR Inhibitors
Current Drug Metabolism Emerging Advances in Nanomedicine as a Nanoscale Pharmacotherapy in Rheumatoid Arthritis: State of the Art
Current Topics in Medicinal Chemistry